Collateral benefit: The comeback of MOG antibodies as a biomarker in neurological practice

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 3, 2015, Pages 243-

  Aktas, Orhan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; BIOLOGICAL MARKER; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; MOG PROTEIN, HUMAN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CELL ASSAY; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL PRACTICE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PROTEIN LOCALIZATION; WESTERN BLOTTING; BLOOD; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; IMMUNOLOGY; MALE;

AUTOANTIBODIES; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 84923182090     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309057     Document Type: Editorial

References (5)

1. Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 2012;5:147-59.
2. Reindl M, Di Pauli F, Rostásy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-61.
3. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265-72.
4. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-7.
5. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.